ClinicalTrials.gov results reporting is the responsible party's obligation, and at a research site the responsible party is not always the sponsor. Under 42 CFR 11.10(a), it is the sponsor of the trial or the principal investigator if so designated, which on an investigator-initiated study usually means your own investigator. Two dates follow from that: registration not later than 21 calendar days after the first participant is enrolled, and results no later than one year after the primary completion date. The FDA spent 2026 reminding people of both. A site that runs even one study under its own investigator needs to know which of its records carry that obligation, and who at the site is watching the clock.
In short
- FDA messaged more than 2,200 sponsors and researchers on March 30, 2026 about more than 3,000 registered trials (FDA, 2026).
- Registration is due 21 calendar days after first enrolment; results one year after the primary completion date (42 CFR 11.24, 11.44).
- FDA's public pre-notice table listed 158 entries when read on September 22, 2026, and its notices table listed 8 Notices of Noncompliance.
- Statutory penalties run to $10,000, plus up to $10,000 a day after 30 days (FDA guidance, adjusted annually for inflation).
What the FDA did in 2026
On April 13, 2026 the agency announced that it had sent messages on March 30 to more than 2,200 drug, biologic and device companies and researchers, covering more than 3,000 registered trials that appeared to be missing required results or to have not completed the quality control review. Commissioner Marty Makary said: "Far too often, companies are suppressing unfavorable clinical trial results and keeping them secret from patients and the scientific community."
Two FDA pages record what follows a reminder. The Pre-Notices for Potential Noncompliance table, content current as of July 13, 2026 and read on September 22, 2026, lists 158 entries; a pre-notice "request[s] that the responsible party address any noncompliance within 30 days after receiving the letter." The Notices of Noncompliance table, content current as of February 5, 2026, lists eight responsible parties, and two of the eight are named individuals rather than companies. That is the detail a site should sit with. The enforcement list is not only pharmaceutical firms.
The two dates, from the regulation
Registration: "not later than December 26, 2007, or 21 calendar days after the first human subject is enrolled, whichever date is later" (42 CFR 11.24(a)).
Results: "no later than 1 year after the primary completion date of the applicable clinical trial" (42 CFR 11.44(a)). Delayed submission with a certification is available in defined cases, such as a trial of a product for which approval of a new use is being sought.
The primary completion date is the trigger, not the study completion date, and not the date the manuscript is ready. A study that finished its primary outcome collection in October 2025 is due now.
Six checks for a site that runs investigator-initiated work
- List every study where your investigator is the responsible party. Open each ClinicalTrials.gov record and read the responsible party field. Industry-sponsored records usually name the sponsor. Anything your site initiated, or any record registered by your own staff, belongs on this list.
- Write down the primary completion date for each one. Then write the date one year later beside it. That second date is the deadline that matters.
- Set the working deadline 90 days early. Results entry is data preparation, not form filling, and the quality control review adds another round. A deadline met on the day is a deadline met by accident.
- Check each record for a pre-notice or a violation flag. A Notice of Noncompliance appears on the study record itself. Both FDA tables are public, searchable and listed by responsible party name.
- Name the account holder and the deputy. The protocol registration account is usually held by one coordinator. When that person leaves, the obligation does not, and an account nobody can open is a missed deadline in waiting.
- Put the two dates into the same tracker as your other expiry dates. Licences, training, financial disclosures, certifications and reporting deadlines are the same kind of problem: dated items with an owner.
The mistake most sites make at step 1
They assume the sponsor takes care of it. On an industry study, usually true. On the study your own principal investigator designed, wrote and registered, the responsible party is that investigator, and the reminder letter arrives with their name on it. The site's regulatory binder covers the documents an inspector asks for; the ClinicalTrials.gov record covers the obligation the public can check from a browser, which is why a missed results submission is visible to anyone reading the study record.
How many records this touches in Michigan
ClinicalTrials.gov's public API, read on September 22, 2026, returns 19,959 study records with at least one Michigan location, of which 2,172 are recruiting and 12,536 are completed. Most of those are multi-site industry studies where the sponsor holds the obligation. The fraction that matters for a site is the investigator-initiated work: the academic collaboration, the device follow-up, the sub-study a principal investigator ran alongside a sponsored protocol. In a state with two large academic health systems and a long tail of independent sites, that fraction is not small, and it is the part with no sponsor project manager behind it.
Where this belongs in site operations
This is a dated-item problem, which is the same shape as the regulatory binder and its expiry dates and the readiness list for an FDA inspection. Our regulatory document tracking for research sites is built for exactly that: every expiration-dated item across studies and staff in one view, escalating reminders, and a missing-item flag per study and per person. The binder stays the system of record and the site stays the responsible party. What the system removes is the chance that the date passed while everybody assumed somebody else was watching it.
Nobody plans to miss a results deadline. They miss it because the primary completion date was in a protocol document and the reminder went to an account a former coordinator opened.
